This novel mechanism has the potential to select resistant, dormant, TrkAIII-expressing NB cells that could re-enter the cell cycle with a more metastatic phenotype, supporting the use of clinically approved Trk inhibitors. This evidence concerns the gene NTRK1 and neuroblastoma.